Antioxidant Therapeutic Clinical Trial in Smith-Lemli-Opitz Syndrome

Project: Research project

Project Details


This application describes the development of a unique Consortium (the Sterol and Isoprenoid Diseases
Research Consortium or STAIR) to study a group of diseases bound by common biochemistry, impact on
health, and rarity: Cerebrotendinous Xanthomatosis (CTX), Hyperimmunoglobulinemia D with Periodic
Fever Syndrome (HIDS), Niemann-Pick Disease Type C (NPC), Sitosterolemia, SjOgren-Larsson Syndrome
(SLS), and Smith-Lemli-Opitz Syndrome (SLOS). STAIR activities will be performed by a team of
investigators chosen for their clinical research strengths and resources, a long history of collaboration, a
diverse geographic distribution to allow maximal access by potential research subjects, their individual
motivation to improve the health of patients, and the commitment of their institution to support the
Consortium. In five years, STAIR will conduct two major clinical studies (a longitudinal natural history study
of NPC and a therapeutic trial to evaluate the efficacy of antioxidant therapy in SLOS), and six pilot research
studies involving patients with either SLS, SLOS, CTX, HIDS or Sitosterolemia. Together with the Intramural
NIH program, the Consortium will support a full-scale training program in the field of sterol and isoprenoid
diseases and share its resources and data with the NIH RDCRN. Participating institutions include Oregon
Health &Science University (OHSU), Eunice Kennedy Shriver National Institute of Child Health and Human
Development, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center, Cincinnati
Children's Hospital Medical Center, University of Nebraska Medical Center, and University of Manitoba
(Canada). OHSU will be the administrative home of the Consortium. Patient support organizations (Smith
Lemli Opitz/RSH Foundation, Hide &Seek Foundation, Ara Parseghian Medical Research Foundation,
Dana's Angels Research Trust, Foundation for Ichthyosis &Related Skin Types, and United
Leukodystrophy Foundation) will participate in Consortium activities. In summary, STAIR will foster
multidisciplinary clinical research, promote training and education and support projects to explore promising
leads in the understanding, diagnostics, and treatment of sterol and isoprenoid diseases.
Effective start/end date7/1/098/31/19


  • National Institutes of Health: $669,749.00
  • National Institutes of Health: $600,001.00
  • National Institutes of Health: $900,000.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.